[{"id":"d694717e-b927-4af3-9e74-7306f9efff05","acronym":"","url":"https://clinicaltrials.gov/study/NCT01188252","created_at":"2021-01-18T04:45:06.986Z","updated_at":"2025-02-25T17:18:29.403Z","phase":"Phase 1","brief_title":"Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 Given in a 3 Days on / 4 Days Off Schedule in Subjects With Advanced Malignancies","source_id_and_acronym":"NCT01188252","lead_sponsor":"Bayer","biomarkers":" CASP3 • CDKN1A • ANXA5","pipe":" | ","alterations":" MCL1 expression","tags":["CASP3 • CDKN1A • ANXA5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MCL1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e roniciclib (BAY1000394)"],"overall_status":"Completed","enrollment":" Enrollment 112","initiation":"Initiation: 08/01/2010","start_date":" 08/01/2010","primary_txt":" Primary completion: 06/01/2016","primary_completion_date":" 06/01/2016","study_txt":" Completion: 12/01/2016","study_completion_date":" 12/01/2016","last_update_posted":"2017-01-09"}]